On January 14, RH director Mark Demilio sold 2,254 shares of company stock for total proceeds of $495,880, reducing his direct holdings by 10.15% to 19,962 shares. The sale was disclosed in an SEC filing and marks the latest in a series of insider transactions this month, following a 2,000-share sale on January 13. Investors often watch such insider moves as potential signals of executive conviction in the company’s near-term prospects.

For the fiscal fourth quarter ended December 11, RH reported revenue of $883.8 million, up 8.9% year-over-year and in line with consensus, but posted earnings per share of $1.71, missing the $2.13 estimate by $0.42. The company’s net margin narrowed to 3.22% and return on equity swung to a negative 161.7%, reflecting elevated leverage. While topline growth remains intact, pressured margins and high debt levels continue to constrain free cash flow generation.

This week Morgan Stanley boosted its price target to $275 and reiterated an overweight rating, citing intact revenue growth and potential multiple expansion. By contrast, Goldman Sachs lowered its target to $144 with a sell rating, while Stifel Nicolaus and Barclays have trimmed theirs to $165 and $283, respectively. The current consensus stands at a hold rating with an average target near $227, reflecting a broad split between bull and bear views on margin recovery and balance-sheet risk.

Institutional ownership remains elevated at over 90%, with recent quarter changes including Clearstead Advisors increasing its stake by 713% to 122 shares and BNP Paribas Asset Management initiating a new position. On the sell side, Durable Capital Partners reduced exposure modestly after raising its stake by 125% last quarter. Mixed buying and selling across major funds suggests divergent views on RH’s ability to sustain top-line momentum while deleveraging its balance sheet.